Merus (MRUS) News Today $39.45 -0.20 (-0.50%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Merus N.V. (MRUS): The Biotech Stock with Biggest Upside PotentialJanuary 17 at 11:37 AM | insidermonkey.comMerus (NASDAQ:MRUS) Short Interest Down 15.5% in DecemberMerus (NASDAQ:MRUS - Get Free Report) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 8,260,000 shares, a drop of 15.5% from the December 15th total of 9,780,000 shares. Based on an average daily volume of 539,100 shares, the short-interest ratio is presently 15.3 days.January 17 at 12:22 AM | marketbeat.comCompanies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In GrowthJanuary 15 at 1:08 PM | finance.yahoo.comBank of America Securities Sticks to Its Buy Rating for Merus (MRUS)January 14 at 10:03 PM | markets.businessinsider.comWhat's Going On With Merus Stock Monday?January 13, 2025 | benzinga.comMerus N.V.: Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsJanuary 13, 2025 | finanznachrichten.deBiohaven, Merus enter research pact and license agreement to develop three ADCsJanuary 13, 2025 | markets.businessinsider.comBiohaven enters multi-target collaboration with MerusJanuary 13, 2025 | markets.businessinsider.comMerus (NASDAQ:MRUS) Sees Unusually-High Trading Volume - What's Next?Merus (NASDAQ:MRUS) Sees Large Volume Increase - What's Next?January 13, 2025 | marketbeat.comBiohaven And Merus Collaborate To Develop Novel Bispecific Antibody Drug ConjugatesJanuary 13, 2025 | markets.businessinsider.comMerus NV (MRUS) and Biohaven Announce Strategic Collaboration on Bispecific Antibody Drug ConjugatesJanuary 12, 2025 | gurufocus.comMerus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsJanuary 12, 2025 | gurufocus.comMerus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsJanuary 12, 2025 | globenewswire.comMerus (NASDAQ:MRUS) Stock Price Up 5.1% - Here's What HappenedMerus (NASDAQ:MRUS) Trading Up 5.1% - What's Next?January 10, 2025 | marketbeat.comJim Cramer Says Merus (MRUS) Still ‘Very Speculative’January 7, 2025 | insidermonkey.comMerus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by BrokeragesMerus (NASDAQ:MRUS - Get Free Report) has been assigned an average recommendation of "Buy" from the fourteen research firms that are covering the firm, Marketbeat reports. Twelve equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendationDecember 28, 2024 | marketbeat.comCanaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)December 17, 2024 | markets.businessinsider.comMerus N.V.: Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCDecember 17, 2024 | finanznachrichten.deMerus NV (MRUS) Initiates Phase 2 Trial for Petosemtamab in Metastatic Colorectal CancerDecember 16, 2024 | gurufocus.comMerus doses first patient in petosemtamab trialDecember 16, 2024 | tipranks.comMerus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCDecember 16, 2024 | globenewswire.comFranklin Resources Inc. Increases Stock Position in Merus (NASDAQ:MRUS)Franklin Resources Inc. raised its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 7.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,256,504 shares of the biotechnology company's stock after buying anDecember 16, 2024 | marketbeat.comLord Abbett & CO. LLC Grows Stock Holdings in Merus (NASDAQ:MRUS)Lord Abbett & CO. LLC increased its holdings in Merus (NASDAQ:MRUS - Free Report) by 83.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 723,988 shares of the biotechnology company's stock after purchasDecember 15, 2024 | marketbeat.comJanus Henderson Group PLC Cuts Stock Holdings in Merus (NASDAQ:MRUS)Janus Henderson Group PLC trimmed its holdings in shares of Merus (NASDAQ:MRUS - Free Report) by 98.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,890 shares of the biotechnology company's stockDecember 15, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Merus (NASDAQ:MRUS - Free Report) by 17.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,200 shareDecember 13, 2024 | marketbeat.comPromising Potential of Merus’s Petosemtamab in HNSCC: A Buy RecommendationDecember 11, 2024 | markets.businessinsider.comMerus (MRUS): FDA Approval and Speculative Future in Cancer TherapyDecember 10, 2024 | insidermonkey.comMerus Positioned for Growth Amid Promising Clinical Data and Resilience to Market FluctuationsDecember 10, 2024 | markets.businessinsider.comCitigroup Increases Merus (NASDAQ:MRUS) Price Target to $97.00Citigroup boosted their target price on Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a research note on Monday.December 10, 2024 | marketbeat.comWellington Management Group LLP Purchases 1,224,573 Shares of Merus (NASDAQ:MRUS)Wellington Management Group LLP grew its position in shares of Merus (NASDAQ:MRUS - Free Report) by 73.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,887,514 shares of the biotechnology company's stock after purchasinDecember 10, 2024 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Merus (MRUS)December 10, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Buy Rating for Merus (MRUS)December 9, 2024 | markets.businessinsider.comMerus’s Promising Prospects: Buy Rating Highlighted by Positive Data on Peto’s Efficacy in HNSCCDecember 9, 2024 | markets.businessinsider.comMerus price target raised to $97 from $89 at CitiDecember 9, 2024 | tipranks.comMerus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $85.00 target price on shares of Merus in a research note on Monday.December 9, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $2.56 Million Stock Position in Merus (NASDAQ:MRUS)The Manufacturers Life Insurance Company lessened its holdings in shares of Merus (NASDAQ:MRUS - Free Report) by 18.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,289 shares of the biotechnoloDecember 9, 2024 | marketbeat.comOptimistic Buy Rating for Merus Driven by Promising Clinical Data and Strategic ExpansionDecember 8, 2024 | markets.businessinsider.comMerus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCCDecember 7, 2024 | markets.businessinsider.comMerus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCCDecember 7, 2024 | globenewswire.comMerus Scores Its First FDA Approval For Lung Cancer DrugDecember 5, 2024 | benzinga.comOptimistic Buy Rating for Merus Driven by Promising Pipeline and Strategic InitiativesDecember 5, 2024 | markets.businessinsider.comFDA Grants Accelerated Approval For Merus' BIZENGRI For Pancreatic Adenocarcinoma And NSCLCDecember 5, 2024 | markets.businessinsider.comStrategic Partnership and Drug Approval Propel Merus to a Buy Rating with $67 TargetDecember 4, 2024 | markets.businessinsider.comMerus Gets FDA Approval for Bizengri TreatmentDecember 4, 2024 | marketwatch.comMerus price target lowered to $109 from $111 at GuggenheimDecember 4, 2024 | finance.yahoo.comMerus gets FDA approval for Bizengri for NRG1+ cancersDecember 4, 2024 | msn.comMerus gets FDA approval of BIZENGRI in NRG1+ Pancreatic Adenocarcinoma, NSCLCDecember 4, 2024 | tipranks.comMerus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy StudyDecember 4, 2024 | globenewswire.comMerus (NASDAQ:MRUS) Stake Lessened by HighVista Strategies LLCHighVista Strategies LLC decreased its position in shares of Merus (NASDAQ:MRUS - Free Report) by 36.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,980 shares of the bioteDecember 3, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Receives Consensus Rating of "Buy" from BrokeragesShares of Merus (NASDAQ:MRUS - Get Free Report) have earned an average recommendation of "Buy" from the fourteen ratings firms that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the compDecember 3, 2024 | marketbeat.com Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Media Mentions By Week MRUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRUS News Sentiment▼0.750.72▲Average Medical News Sentiment MRUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRUS Articles This Week▼145▲MRUS Articles Average Week Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Today Vaxcyte News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today Blueprint Medicines News Today BridgeBio Pharma News Today Legend Biotech News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRUS) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRUS Stock Alerts